Related Experiment Video
Updated: Feb 13, 2026

Fabrication and Characterization of Griffithsin-modified Fiber Scaffolds for Prevention of Sexually Transmitted Infections
Published on: October 31, 2017
In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens
Susanne Paukner1, Astrid Gruss2, Jørgen Skov Jensen3
1Nabriva Therapeutics GmbH, Vienna, Austria susanne.paukner@nabriva.com.
Abstract:
The pleuromutilin antibiotic lefamulin demonstrated in vitro activity against the most relevant bacterial pathogens causing sexually transmitted infections (STI), including Chlamydia trachomatis (MIC50/90, 0.02/0.04 mg/liter; n = 15), susceptible and multidrug-resistant Mycoplasma genitalium (MIC range, 0.002 to 0.063 mg/liter; n = 6), and susceptible and resistant Neisseria gonorrhoeae (MIC50/90, 0.12/0.5 mg/liter; n = 25). The results suggest that lefamulin could be a promising first-line antibiotic for the treatment of STI, particularly in populations with high rates of resistance to standard-of-care antibiotics.
Insights
Lefamulin shows strong in vitro activity against key bacteria causing sexually transmitted infections (STIs). This pleuromutilin antibiotic is a potential new treatment option, especially where resistance to current drugs is high.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Sexually transmitted infections (STIs) pose a significant global health challenge.
- Rising antimicrobial resistance necessitates the development of novel therapeutic agents.
- The pleuromutilin antibiotic class offers a potential avenue for new STI treatments.
Purpose of the Study:
- To evaluate the in vitro activity of lefamulin against major bacterial pathogens responsible for STIs.
- To assess lefamulin's efficacy against drug-susceptible and drug-resistant strains of Chlamydia trachomatis, Mycoplasma genitalium, and Neisseria gonorrhoeae.
Main Methods:
- In vitro antimicrobial susceptibility testing was performed.
- Minimum Inhibitory Concentrations (MIC50/90 and MIC range) were determined for lefamulin.
- Standardized bacterial strains of Chlamydia trachomatis, Mycoplasma genitalium, and Neisseria gonorrhoeae were utilized.
Main Results:
- Lefamulin exhibited potent in vitro activity against Chlamydia trachomatis (MIC50/90, 0.02/0.04 mg/liter).
- Lefamulin demonstrated significant activity against Mycoplasma genitalium, including multidrug-resistant strains (MIC range, 0.002 to 0.063 mg/liter).
- Lefamulin showed promising activity against both susceptible and resistant Neisseria gonorrhoeae (MIC50/90, 0.12/0.5 mg/liter).
Conclusions:
- Lefamulin displays broad-spectrum in vitro activity against key bacterial STI pathogens.
- Lefamulin represents a potential first-line antibiotic for STI treatment.
- Its efficacy is particularly relevant for populations experiencing high rates of resistance to existing therapies.
Related Concept Videos
Sexually Transmitted Infections
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Male Sexual Response: Erection & Ejaculation
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Development of the Sexual Organs in the Embryo and Fetus
Near the gonadal ridges, two duct systems are present: the mesonephric ducts (Wolffian ducts) and paramesonephric ducts (Müllerian ducts). These ducts form the basis for the...
Bacterial Transformation
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
Bacterial Signaling

